Patient Guide: A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 8 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06761677
Status: 🟢 Enrolling Now
Condition: Relapsed or Refractory Lymphoma Including ENKL
Phase: PHASE1, PHASE2

Where You Can Participate

This study is available at 8 locations across the country.

Top locations include:
  • • Hong Kong,
  • • Bunkyō-Ku,
  • • Chuo-ku,
  • • And 5 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma - Join Clinical Trial NCTNCT06761677

How to Join This Clinical Trial - NCTNCT06761677

Learn how to participate in this PHASE1, PHASE2 trial studying an investigational therapy for Relapsed or Refractory Lymphoma Including ENKL. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Relapsed or Refractory Lymphoma Including ENKL. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Relapsed or Refractory Lymphoma Including ENKL
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1, PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06761677 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 8 locations. Find a study site near you:

Clinical Research Site

Hong Kong, - China

Status: RECRUITING

Clinical Research Site

Bunkyō-Ku, - Japan

Status: RECRUITING

Clinical Research Site

Chuo-ku, - Japan

Status: RECRUITING

Clinical Research Site

Koto-ku, - Japan

Status: RECRUITING

Clinical Research Site

Kyoto, - Japan

Status: RECRUITING

Clinical Research Site

Okayama, - Japan

Status: RECRUITING

Clinical Research Site

Tsu, - Japan

Status: RECRUITING

Clinical Research Site

Singapore, - Singapore

Status: RECRUITING

How to Enroll in This Study

To learn more about participating in this PHASE1, PHASE2 clinical trial for Relapsed or Refractory Lymphoma Including ENKL:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships